REG - Seed Innovations Ltd - Investee Company Update: Little Green Pharma Ltd

Seed InnovationsAnnouncement

Wed 12:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250430:nRSd8637Ga&default-theme=true

RNS Number : 8637G  Seed Innovations Limited  30 April 2025

Seed Innovations Ltd / AIM: SEED / Sector: Closed End Investments

30 April 2025

SEED Innovations Limited

("SEED" or the "Company")

 

Investee Company Update: Little Green Pharma Ltd

 

Robust double-digit year-on-year growth

 

SEED Innovations Ltd, the AIM-quoted investment company offering exposure to
disruptive, high-growth, life sciences and technology ventures typically
inaccessible to everyday investors, is pleased to note that its portfolio
company, Little Green Pharma Ltd ('LGP'), has published its quarterly
activities report and Appendix 4C for the period ending 31 March 2025 on the
ASX.

 

The Company owns 7,324,796 ordinary shares in LGP representing 2.43% of LGP's
issued share capital.

 

Commenting on the announcement, Ed McDermott, SEED CEO, said: "LGP continues
to deliver strong double-digit year-on-year growth, with cash receipts
surpassing A$10 million in the quarter ended 31 March 2025. The company
remains in a solid financial position, with net tangible assets significantly
outweighing its enterprise value and minimal long-term debt. Increasing sales
momentum in Germany and the UK further reinforces LGP's strategic direction,
and we remain confident in the company's ability to sustain this positive
trajectory."

 

The following excerpt from the announcement, which was released on the ASX, is
set out without any material changes.

 

Little Green Pharma Ltd

 

Quarterly Activities Report and Appendix 4C

 

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to
provide its activities report and Appendix 4C for the quarter ending 31 March
2025.

 

Highlights

·    LGP FY25 revenue of $36.6 million (unaudited) representing over 40%
growth from prior year, with Health House generating further $0.8 million in
third party product sales in two months post-acquisition

·    LGP revenue of $9.6 million (unaudited) for quarter, up over 30% from
prior corresponding period with record March month of $4.0 million (unaudited)

·    Cash receipts including Health House of $10.3 million up nearly 30%
from prior corresponding period

·    Successful acquisition and integration of Health House distribution
business

·    NAB loan facilities extended to 30 June 2027

·    French national cannabis legislation submitted to European
Commission; commercial access expected late CY25 / early CY26

·    12-month QUEST results released and published in PLOS One journal
with results showing long-term efficacy of LGP medicinal cannabis for various
chronic conditions

·    Department of Veterans Affairs confirmed funding of MDMA and
Psilocybin assisted therapies for veterans with post-traumatic stress disorder
and treatment resistant depression

·    Strengthening of board with appointment of Mr Paul Long as Managing
Director and Mr David Fenlon as an Independent Non Executive Director

·    Cash in bank of $2.4 million

 

The announcement in full can be accessed from the following link:
https://www.investlittlegreenpharma.com/site/showdownloaddoc.aspx?AnnounceGuid=715a80ae-ca84-4a24-9aff-d8791e2321c4
(https://www.investlittlegreenpharma.com/site/showdownloaddoc.aspx?AnnounceGuid=715a80ae-ca84-4a24-9aff-d8791e2321c4)

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation No. 596/2014, which forms part of United Kingdom domestic law by
virtue of the European Union (Withdrawal) Act 2018 (as amended).

 

- Ends -

 

For further information on the Company please visit: www.seedinnovations.co
(http://www.seedinnovations.co/)  or contact:

 

 Ed McDermott        SEED Innovations Ltd             E: info@seedinnovations.co 

 Lance de Jersey                                       
 James Biddle        Beaumont Cornish Limited,        T: (0)20 7628 3396

 Roland Cornish      Nomad                             
 Isabella Pierre     Shard Capital Partners LLP       T: (0)20 7186 9927

 Damon Heath         Broker
 Ana Ribeiro         St Brides Partners Ltd,          E: seed@stbridespartners.co.uk

 Isabel de Salis     Financial PR

 

NOTES

Seed Innovations Ltd

Seed Innovations Ltd is an AIM quoted investment company offering exposure to
disruptive, high-growth, life sciences and technology ventures typically
inaccessible to everyday investors. Its strategy focuses on identifying
early-stage opportunities with upcoming investment catalysts, alongside more
mature investments providing near-term liquidity. With a portfolio of such
investments and cash reserves, the Company is agile and poised to capitalise
swiftly on new investment opportunities.

 

Nominated Adviser

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated
Adviser and is authorised and regulated by the FCA. Beaumont Cornish's
responsibilities as the Company's Nominated Adviser, including a
responsibility to advise and guide the Company on its responsibilities under
the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed
solely to the London Stock Exchange. Beaumont Cornish is not acting for and
will not be responsible to any other persons for providing protections
afforded to customers of Beaumont Cornish nor for advising them in relation to
the proposed arrangements described in this announcement or any matter
referred to in it.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUEAFLEDENSEFA